Antibiotic boosts radiation in lung cancer? early safety trial launches
NCT ID NCT03546829
First seen Jan 15, 2026 · Last updated May 15, 2026 · Updated 14 times
Summary
This early-stage study tests whether adding the antibiotic vancomycin to precision radiation is safe for people with non-small cell lung cancer that has started to grow in a few spots. Ten participants will receive vancomycin for one week before and one month after radiation, with stool and blood samples collected. The main goal is to check for severe diarrhea and measure immune system changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY STAGE NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.